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Background: Whether rosiglitazone may affect the risk of non-melanoma skin cancer (NMSC) has not been investigated.
Methods: The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the
National Health Insurance. An entry date was set at 1 January 2006 and a total of 886418 patients with type 2 diabetes
were followed up for NMSC incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of
rosiglitazone exposure (using tertile cutoffs of duration of therapy and cumulative dose) were calculated and hazard ratios
estimated by Cox regression. Additional models were created as sensitivity analyses.
Results: There were 103097 ever-users and 783321 never-users, respective numbers of incident NMSC 250 (0.24%) and
2084 (0.27%), and respective incidence 68.90 and 76.77 per 100000 person-years. Although the overall hazard ratio was
not significant in the unadjusted, age-sex-adjusted or fully adjusted model, the risk was significantly lower in the third
tertile of duration of therapy and cumulative dose, with significant P for trends. The fully adjusted hazard ratio (95%
confidence interval) for a duration of therapy >13.77 months and a cumulative dose of >1752 mg was 0.723 (0.566,
0.923) and 0.783 (0.618, 0.993), respectively. The findings were supported by various sensitivity analyses.
Conclusions: Rosiglitazone may reduce the risk of NMSC, but further confirmation is required.
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All three isotypes of peroxisome proliferator-activator
receptors (PPARs), i.e., PPARα, PPARβ/δ and PPARγ, are
expressed in human skin keratinocytes [1,2]. They play
important roles in skin barrier permeability, proliferation
inhibition, differentiation promotion, immune regulation,
and sebum production [1,3].
PPARβ/δ is the most predominant isotype in human
keratinocytes, and it is upregulated during wound healing
[1]. PPARα is closely related to lipid metabolism; and
plays an important role in skin barrier development [1].
PPARγ activation has been shown to inhibit proliferation,
promote differentiation and induce apoptosis in various
malignant tissues; and its agonists have been used as
therapeutic agents for psoriasis, a benign skin disease
characterized by epidermal hyperplasia [1,4-6].Correspondence: ccktsh@ms6.hinet.net
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unless otherwise stated.The use of PPAR agonists or antagonists in the treat-
ment of many skin diseases including acne vulgaris, psor-
iasis, benign skin tumors and skin cancer is of clinical
importance but still awaits in-depth investigation [2].
Whether PPARγ has a role in the prevention or treatment
of skin cancer is under debate [2]. Reduced PPARγ activity
is noted in mice susceptible to skin cancer induced by
dimethylbenz[a]anthracene [7], but activation of PPARγ
with rosiglitazone treatment does not prevent the devel-
opment of skin tumors induced by ultraviolet light or
chemical such as dimethylbenz[a]anthracene/12-O-tetra-
decanoylphorbol-13-acetate in mice [8]. However, a later
study by the same group did show that rosiglitazone may
reduce the occurrence of skin cancer in transgenic mice
overexpressing insulin-like growth factor 1 (IGF1) [9].
To our knowledge, there is only one paper evaluating
the risk of non-melanoma skin cancer (NMSC) in patients
who had used thiazolidinediones (a class of PPARγ
agonists used for glycemic control in patients with type 2
diabetes mellitus) by using the General Practice Research
Database in the United Kingdoms [10]. The investigatorsan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ous thiazolidinediones used by the patients.
In an early study conducted in keratinocytes in mono-
layer culture and in human whole skin organ culture, rosi-
glitazone (one of the thiazolidinediones used in clinical
practice) inhibits proliferation, motility, and matrix metal-
loproteinase production in keratinocytes more effectively
than the other PPARγ agonist pioglitazone does [11]. In
consideration of the better performance of rosiglitazone
on the inhibition of keratinocyte proliferation [11], and
the recently reported potential risk of bladder cancer
related to pioglitazone [12-14], the present study aimed at
evaluating the association between rosiglitazone use and
NMSC in Taiwanese patients with type 2 diabetes mellitus
by using the reimbursement databases of the National
Health Insurance (NHI).
Methods
The study was approved by an ethic review board of the
National Health Research Institutes with registered
approval number 99274.
Since March 1995, a compulsory and universal system of
health insurance (the so-called NHI) was implemented in
Taiwan. All contracted medical institutes must submit com-
puterized and standard claim documents for reimburse-
ment. More than 99% of citizens are enrolled in the NHI,
and >98% of the hospitals nationwide are under contract
with the NHI. The average number of annual physician
visits in Taiwan is one of the highest around the world, at
approximately 15 visits per year per capita in 2009.
The National Health Research Institutes is the only
organization approved, as per local regulations, for hand-
ling the NHI reimbursement databases for academic
research. The databases contain detailed records on every
visit for each patient, including outpatient visits, emer-
gency department visits and hospital admission. The data-
bases also include principal and secondary diagnostic
codes, prescription orders, and claimed expenses.
The identification information of the individuals was
scrambled for the protection of privacy. Diabetes was
coded 250.XX and NMSC 173, based on the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM).
The databases of all patients who had been diagnosed
with diabetes and under treatment with either oral anti-
diabetic agents or insulin during the period of 1996–2009
from the whole nation, and who remained enrolled in the
NHI after 2006 (n = 1446414) were first retrieved. A total
of 235287 patients who had ever been treated with pioglit-
azone were then excluded to avoid the possible contamin-
ation by its use because it may increase the risk of some
cancer like bladder cancer [15]. The selected entry date
was 1 January 2006. After excluding patients who had a
diagnosis of diabetes after the year 2006 (n = 342351),patients who held a Severe Morbidity Card as having type
1 diabetes (n = 7120, in Taiwan, patients with type 1 dia-
betes were issued a so-called “Severe Morbidity Card”
after certified diagnosis and they were waived for much of
the co-payments), patients having a diagnosis of NMSC
before 2006 (n = 6297), those who died (n = 96320) or
withdrew from the NHI (n = 12502) before entry date,
duplicated identification number (n = 106), and unclear
information on date of birth or sex (n = 5123), a total of
886418 patients with a diagnosis of type 2 diabetes melli-
tus and under therapy with oral anti-diabetic agents
(except pioglitazone) or insulin were recruited.
Those who had ever been prescribed with rosiglitazone
before entry date were defined as ever-users; and never-
users were defined as those who had never been pre-
scribed with rosiglitazone before entry date. To evaluate
whether a dose–response relationship could be seen
between rosiglitazone and NMSC, the tertile cutoffs for
duration of therapy in months and cumulative dose in mg
were calculated from the databases and used for analyses.
An entry date at the beginning of 2006 was used based
on the following reasons: 1) Because rosiglitazone was
marketed in 2001 in Taiwan, this entry date, being in the
middle of the marketing date of rosiglitazone in Taiwan
and the ending date of the available NHI databases in
2009, provided a longest exposure of 4 to 5 years at
entry and at the same time a longest follow-up duration
of 4 years; and 2) The issue of bladder cancer associated
with pioglitazone noted in the PROspective pioglitAzone
Clinical Trial In macroVascular Events (PROactive)
was published in 2005 [16], and in 2007, the safety of
rosiglitazone has been challenged with a risk of acute
myocardial infarction [17]. These had caused tremen-
dous prescription behavior changes in the physicians to
withdraw thiazolidinediones including rosiglitazone and
pioglitazone (troglitazone has not been marketed in
Taiwan) and the patients might have stopped taking the
drugs even if they were prescribed after the year 2006.
Therefore, the use of a later entry date would make the
estimation of the duration of therapy and cumulative
dose of rosiglitazone less reliable. In addition, this
would also shorten the follow-up duration for cancer
incidence.
All comorbidities and covariates were determined as a
status/diagnosis before the entry date. The ICD-9-CM
codes for the comorbidities were [18-21]: nephropathy
580–589, hypertension 401–405, chronic obstructive
pulmonary disease (a surrogate for smoking) 490–496,
cerebrovascular disease 430–438, ischemic heart disease
410–414, peripheral arterial disease 250.7, 785.4, 443.81
and 440–448, eye disease 250.5, 362.0, 369, 366.41 and
365.44, obesity 278, dyslipidemia 272.0-272.4, and cancer
other than NMSC 140–208 (excluding 173). Medications
included sulfonylurea, metformin, insulin, and acarbose.
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users of rosiglitazone were compared by Chi-square test.
The incidence density of NMSC was calculated for
ever-users and never-users and for different subgroups
of exposure. Chi-square test was used to compare the
distribution of incident cases of NMSC in ever-users
versus never-users and among the different subgroups
of dose–response parameters. The numerator for the
incidence was the number of patients with incident
NMSC during the 4-year follow-up, and the denomin-
ator was the person-years of follow-up. For ever-users,
the follow-up duration was either censored at the date
of NMSC diagnosis or at the date of the last record of
the available reimbursement databases in individuals
without incident NMSC. For never-users, the follow-
up was censored at the date of rosiglitazone initiation
or NMSC diagnosis or the last reimbursement record,
depending on whichever occurring first. This ensured
no exposure to rosiglitazone throughout the whole
follow-up period until censor in the referent group of
never-users.
Cox proportional hazards regression was performed to
estimate the hazard ratios for NMSC for ever-users ver-
sus never-users, and for the various subgroups of dose–
response parameters. The following three models were
created: 1) unadjusted; 2) adjusted for age and sex; and
3) adjusted for all variables compared previously as base-
line characteristics between ever-users and never-users.
The following fully adjusted models were also created
as sensitivity analyses: 1) resetting the entry date to 1
January 2005; 2) deleting patients who developed
NMSC within 3 months of follow-up; 3) excluding
patients with a history of any cancer before 2006; 4)
including pioglitazone users in the analyses; 5) using a
time-dependent approach; and 6) excluding never-users
of rosiglitazone and conducting the analyses only
among rosiglitazone ever-users by comparing the sec-
ond and third tertiles of exposure versus the first ter-
tiles as referents.
Analyses were conducted using SAS statistical software,
version 9.3 (SAS Institute, Cary, NC). P < 0.05 was consid-
ered statistically significant.
Results
Table 1 compares the baseline characteristics between
ever-users (n = 103097) and never-users (n = 783321) of
rosiglitazone. All of the variables differed significantly be-
tween the two groups. Ever-users are characterized by
older age distribution, higher proportion with a diabetes
duration ≥5 years, higher proportions of all comorbidities
and other cancer, higher proportions of using other
medications.
Table 2 shows the incidences of NMSC between ever-
users and never-users of rosiglitazone, and among thedifferent categories of the dose–response parameters for
rosiglitazone exposure. The incidence rate in never-users
and ever-users of rosiglitazone was 76.77 and 68.90 per
100000 person-years, respectively.
Table 3 shows the hazard ratios with regards to different
categories of rosiglitazone exposure. In the models evalu-
ating the overall hazard ratios for ever-users versus never-
users, the hazard ratios were not significant in all three
models. However, in the models evaluating the dose–re-
sponse exposure to rosiglitazone with regards to duration
of therapy and cumulative dose, a significantly lower risk
could be seen in the third tertiles and the trend analyses.
The sensitivity analyses are shown in Table 4. Generally
speaking, the results were consistent with the full models
in the original analyses (Table 3). Although the overall
hazard ratios were not significant, the third tertiles of
rosiglitazone exposure were generally associated with a
significantly lower risk of NMSC. In the time-dependent
analyses, an approximately 30% higher risk was observed
for the first tertiles of duration of therapy and cumulative
dose, but the third tertiles remained significantly associ-
ated with a lower risk. In the analyses comparing the
second and third tertiles of rosiglitazone exposure versus
the first tertiles as referent by including only rosiglitazone
ever-users, the hazard ratio (95% confidence interval) for
the second and third tertile of duration of therapy was
0.850 (0.634, 1.140) (P = 0.2777) and 0.639 (0.465, 0.876)
(P = 0.0054), respectively (P-trend = 0.0054); and was
0.852 (0.633, 1.148) and 0.712 (0.521, 0.973), respectively,
for cumulative dose (P-trend = 0.0327).
Discussion
This is the first observational cohort study evaluating the
risk of NMSC associated with the specific use of rosiglita-
zone in patients with type 2 diabetes mellitus. The findings
suggested a reduced risk in patients who had used the drug
for more than 13 months or with a cumulative dose of
greater than 1750 mg (Table 3). The results of such a
promising effect provided rationale for further in-depth in-
vestigation on this drug in the prevention of NMSC.
The findings were consistent in various sensitivity ana-
lyses, except in the time-dependent models that showed a
significantly higher risk in the first tertiles of rosiglitazone
exposure (Table 4). In the analyses for the incidence of
NMSC, patients in the first tertiles of rosiglitazone expos-
ure also showed a slightly higher incidence than the refer-
ent groups of never-users of rosiglitazone (Table 2). This
could result from residual confounding among users of a
short duration (i.e., in the first tertiles of exposure) be-
cause rosiglitazone is always used as a second or third line
drug for glucose lowering in clinical practice. At the
inception of its use, patients are usually characterized by
older age, a longer duration of diabetes (Table 1) and
poorer glycemic control (data not available), which might
Table 1 Baseline characteristics between never-users and ever-users of rosiglitazone
Variables Never-users Ever-users P
n % n %
n = 886418 783321 103097
Age (years)
<40 33874 4.32 3269 3.17 <0.0001
40-49 102887 13.13 11623 11.27
50-59 199819 25.51 27204 26.39
60-69 200241 25.56 29608 28.72
≥70 246500 31.47 31393 30.45
Sex (men) 399333 50.98 49282 47.80 <0.0001
Diabetes duration (years)
<1 70381 8.98 1434 1.39 <0.0001
1-3 133250 17.01 7184 6.97
3-5 123610 15.78 11094 10.76
≥5 456080 58.22 83385 80.88
Hypertension 443728 56.65 77740 75.40 <0.0001
Chronic obstructive pulmonary disease 114018 14.56 24177 23.45 <0.0001
Cerebrovascular disease 116947 14.93 25453 24.69 <0.0001
Nephropathy 93744 11.97 23717 23.00 <0.0001
Ischemic heart disease 174225 22.24 40511 39.29 <0.0001
Peripheral arterial disease 89324 11.40 24510 23.77 <0.0001
Eye disease 63803 8.15 21179 20.54 <0.0001
Obesity 11423 1.46 1961 1.90 <0.0001
Dyslipidemia 371714 47.45 69015 66.94 <0.0001
Other cancer prior to baseline 93619 11.95 13058 12.67 <0.0001
Sulfonylurea 577003 73.66 99140 96.16 <0.0001
Metformin 512063 65.37 96850 93.94 <0.0001
Acarbose 80640 10.29 38971 37.80 <0.0001
Insulin 102359 13.07 39119 37.94 <0.0001
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development.
Exposure to ultraviolet sunlight may be the most im-
portant risk factor for skin cancer; and other risk factors
may include family history, fair skin, light eyes, and im-
munosuppression [22]. It should be admitted that most
of these potential confounders could not be adjusted
for in the present study because of the lack of such
information in the reimbursement databases. Therefore,
the beneficial effect of rosiglitazone on the prevention of
NMSC should better be confirmed in future studies con-
sidering the adjustment for these potential confounders.
Misclassification of NMSC might occur in the present
study. However, such a probability was low because la-
beled diagnoses should be printed out in all prescrip-
tions handed to the patients, and mislabeling of a cancer
diagnosis would not be acceptable to the patients when
they saw the diagnosis.Because the present study recruited only patients with
type 2 diabetes mellitus, the results should not be readily
generalized to non-diabetic individuals. The animal stud-
ies conducted by He et al. have provided good reasons
for this cautiousness. In ordinary mice treated with car-
cinogens, rosiglitazone does not reduce skin cancer risk
[8], but rosiglitazone does reduce skin cancer risk in
transgenic mice overexpressing IGF1 [9]. The authors
explained that ultraviolet light and carcinogenic chemicals
may activate some carcinogenic pathways enabling kerati-
nocytes to bypass the IGF1 signaling; and that rosiglita-
zone may possibly inhibit the development of skin cancer
through activation of AMP-activated protein kinase with
subsequent inhibition of IGF1-induced mammalian target
of rapamycin activity and phosphorylation of p70S6 kinase
[9]. Patients with type 2 diabetes mellitus are at an in-
creased risk of cancer and they are characterized by insu-
lin resistance with hyperinsulinemia and hyperactivity in
Table 2 Incidence of non-melanoma skin cancer by rosiglitazone exposure at entry
Rosiglitazone use Case number Incident skin
cancer
% Person-years Incidence rate
(per 100,000 person-years)
Never users 783321 2084 0.27 2714745.08 76.77
Ever users 103097 250 0.24 362846.42 68.90
P value 0.1653
Duration of therapy (months)
Never users 783321 2084 0.27 2714745.08 76.77
<3.73 33039 93 0.28 112752.67 82.48
3.73-13.77 35108 88 0.25 123278.50 71.38
>13.77 34950 69 0.20 126815.25 54.41
P value 0.0847
Cumulative dose (mg)
Never users 783321 2084 0.27 2714745.08 76.77
<448 32942 90 0.27 112711.50 79.85
448-1752 35078 86 0.25 123002.83 69.92
>1752 35077 74 0.21 127132.08 58.21
P value 0.2172
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to clarify the usefulness of rosiglitazone on the prevention
of skin cancer in individuals without diabetes mellitus.
This study has several strengths. Because the databases
were derived from the whole population and they
spanned the whole period from the beginning of the
marketing of rosiglitazone from 2001 in Taiwan to the
end of 2009, there was no concern of potential selection
bias related to sampling error. The databases included
all claim records on outpatient visits, emergency depart-
ment visits and hospital admission, and we caught the




HR 95% CI P HR
Ever users 0.882 (0.773, 1.005) 0.0602 0.908
Duration of therapy (months)
<3.73 1.059 (0.861, 1.304) 0.5862 1.109
3.73-13.77 0.903 (0.730, 1.118) 0.3507 0.941
>13.77 0.703 (0.553, 0.893) 0.0039 0.705
P-trend 0.0072
Cumulative dose (mg)
<448 1.025 (0.830, 1.265) 0.8221 1.070
448-1752 0.885 (0.713, 1.098) 0.2675 0.912
>1752 0.752 (0.596, 0.948) 0.0157 0.764
P-trend 0.0139
Referent group: never-users of rosiglitazone; HR: hazard ratio, CI: confidence interva
*Adjusted for all variables in Table 1.morbidity by the NHI and most medical co-payments
can be waived. Furthermore, there is a low drug cost-
sharing required by the NHI and patients with certain
conditions such as low-income household, veterans or
patients with prescription refills for chronic disease are
exempted from the drug cost-sharing. Therefore the
detection rate of NMSC would not tend to differ among
different social classes. The use of medical records also
reduced the potential bias related to self-reporting.
The study limitations included a lack of actual measure-
ment data for potential confounders such as sunlight
exposure, occupation history, family history, lifestyle, diet,non-melanoma skin cancer
djusted Fully adjusted*
95% CI P HR 95% CI P
(0.796, 1.036) 0.1513 0.927 (0.807, 1.066) 0.2865
(0.901, 1.365) 0.3295 1.119 (0.905, 1.383) 0.2985
(0.760, 1.165) 0.5744 0.961 (0.773, 1.196) 0.7243
(0.555, 0.896) 0.0043 0.723 (0.566, 0.923) 0.0094
0.0171 0.0386
(0.867, 1.322) 0.5276 1.081 (0.872, 1.341) 0.4773
(0.735, 1.132) 0.4033 0.931 (0.747, 1.161) 0.5270
(0.606, 0.963) 0.0228 0.783 (0.618, 0.993) 0.0436
0.0337 0.0743
ls.
Table 4 Sensitivity analyses estimating hazard ratios for non-melanoma skin cancer associated with rosiglitazone exposure
Rosiglitazone use Setting entry date to 1
January 2005
Deleting patients who
developed skin cancer within
3 months of follow-up
Excluding patients with a history
of any cancer before 2006
Including pioglitazone
users in the analyses
Time-dependent models
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Ever users 0.986 (0.882, 1.102) 0.7977 0.933 (0.809, 1.075) 0.3368 0.951 (0.834, 1.083) 0.4469 0.938 (0.835, 1.055) 0.2863 0.909 (0.785, 1.051) 0.1981
Duration of therapy (months)
<3.73 1.177 (0.975, 1.421) 0.0903 1.119 (0.900, 1.392) 0.3106 1.055 (0.855, 1.302) 0.6199 1.114 (0.930, 1.336) 0.2411 1.287 (1.050, 1.579) 0.0153
3.73-13.77 1.112 (0.939, 1.318) 0.2189 0.989 (0.792, 1.234) 0.9194 1.096 (0.906, 1.325) 0.3452 1.025 (0.862, 1.219) 0.7781 1.059 (0.851, 1.317) 0.6099
>13.77 0.787 (0.662, 0.935) 0.0065 0.713 (0.554, 0.918) 0.0087 0.737 (0.592, 0.916) 0.0060 0.718 (0.589, 0.874) 0.0010 0.583 (0.457, 0.740) <0.0001
P-trend 0.1215 0.0484 0.0871 0.0186 0.0024
Cumulative dose (mg)
<448 1.138 (0.939, 1.379) 0.1883 1.092 (0.876, 1.361) 0.4336 0.985 (0.793, 1.223) 0.8882 1.059 (0.880, 1.275) 0.5418 1.286 (1.030, 1.607) 0.0264
448-1752 1.099 (0.929, 1.301) 0.2722 0.923 (0.735, 1.159) 0.4892 1.105 (0.915, 1.334) 0.3015 1.011 (0.849, 1.203) 0.9047 0.983 (0.775, 1.247) 0.8876
>1752 0.815 (0.687, 0.966) 0.0186 0.798 (0.627, 1.016) 0.0672 0.780 (0.630, 0.965) 0.0224 0.773 (0.638, 0.936) 0.0084 0.614 (0.476, 0.792) 0.0002
P-trend 0.1839 0.0971 0.1685 0.0482 0.0041
Referent group: never-users of rosiglitazone; HR: hazard ratio, CI: confidence intervals.
In models excluding patients not treated with rosiglitazone and using the first tertile of exposure as referent, the hazard ratio (95% confidence interval) for the second and third tertile of duration of therapy was 0.850
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biochemical data for evaluating their impact. Another
limitation is the lack of information on the histopathology,
grading and staging of NMSC.
In summary, this study first reports a potential benefi-
cial effect of the use of rosiglitazone on the prevention
of NMSC in patients who have been using the medica-
tion for more than 13 months or with a cumulative dose
of greater than 1750 mg.
Conclusions
This large population-based retrospective cohort study
in Taiwan suggests that prolonged use of rosiglitazone in
patients with type 2 diabetes mellitus may be associated
with a lower risk of NMSC. Exploring the potential use
of rosiglitazone as a preventive and/or therapeutic agent
for NMSC is an interesting issue with clinical import-
ance. However, more researches are required to confirm
the findings of the present study.
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